Endogenous C1-inhibitor production and expression in the heart after acute myocardial infarction

Reindert W Emmens1, Umit Baylan2, Lynda J M Juffermans3

  • 1Department of Pathology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands; Institute for Cardiovascular Research, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands; Department of Immunopathology, Sanquin Research, Postbus 9892, 1006 AN, Amsterdam, The Netherlands.

Insights

Endogenous C1-inhibitor is expressed in the heart after myocardial infarction, suggesting it regulates complement activity. This protein is likely produced locally in the heart following injury.

Area of Science:

  • Cardiovascular Research
  • Immunology
  • Molecular Biology

Background:

  • Complement activation exacerbates inflammation and damage post-myocardial infarction.
  • Understanding regulators of post-infarction complement activation is crucial.
  • Endogenous C1-inhibitor's role in the heart after myocardial infarction was investigated.

Purpose of the Study:

  • To determine if endogenous C1-inhibitor is expressed in the heart after acute myocardial infarction.
  • To investigate the localization and timing of C1-inhibitor expression.
  • To explore potential local production of C1-inhibitor in the heart.

Main Methods:

  • Immunohistochemistry analyzed C1-inhibitor and complement products (C3d, C4d) in human myocardial infarction samples (n=28) and controls (n=8).
  • Cardiac serping1 (C1-inhibitor gene) transcript levels were measured in rats post-myocardial infarction using microarrays.
  • C1-inhibitor expression was assessed in human endothelial cells and rat cardiomyoblasts in vitro under ischemic conditions.

Main Results:

  • C1-inhibitor protein was found in cardiomyocytes within necrotic infarct cores (12h-5days post-MI).
  • C1-inhibitor expression temporally and spatially coincided with complement activation products (C3d, C4d).
  • Rat hearts showed increased serping1 transcripts from 2h to 7days post-MI; in vitro studies revealed increased C1-inhibitor in stressed endothelial cells and cardiomyoblasts.

Conclusions:

  • Endogenous C1-inhibitor appears to regulate myocardial complement activity post-myocardial infarction.
  • Evidence suggests C1-inhibitor is locally produced within the heart following acute myocardial infarction.
  • These findings highlight a potential endogenous protective mechanism in cardiac injury.
Abstract

Related Concept Videos

Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
585
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.2K
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.7K